NON RARE IN EUROPE: Eosinophilic esophagitis

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:73247
Who is this for?
Show terms as
2FDA treatments18Active trials8Treatment centers2Financial resources

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Eosinophilic esophagitis, often called EoE for short, is a chronic condition where a type of white blood cell called an eosinophil builds up in the esophagus — the tube that carries food from your mouth to your stomach. Normally, eosinophils are not found in the esophagus, but in EoE they gather there and cause inflammation, which makes swallowing difficult and painful over time. EoE is considered an allergic or immune-driven disease, and it is closely linked to food allergies and environmental allergies like pollen. The most common symptoms include trouble swallowing solid foods, food getting stuck in the throat or chest, heartburn that does not respond well to standard acid-reducing medicines, chest pain, and in children, poor growth or refusal to eat. Symptoms can vary a lot between children and adults. Children may show up as picky eaters or have poor weight gain, while adults more often notice food getting stuck. Treatment focuses on reducing inflammation and managing triggers. The main approaches include dietary changes (removing common food allergens like milk, wheat, eggs, soy, nuts, and seafood), swallowed corticosteroid medications (like budesonide or fluticasone), and proton pump inhibitors (acid-reducing drugs). In 2022, the FDA approved dupilumab (Dupixent) as the first biologic drug specifically for EoE in adults and adolescents. Endoscopic dilation may be needed if the esophagus has narrowed. With proper management, most people with EoE can live well, though the condition is usually lifelong.

Also known as:

Key symptoms:

Difficulty swallowing, especially solid foodsFood getting stuck in the throat or chest (food impaction)Heartburn or chest pain that does not improve with standard antacidsNausea or vomitingAbdominal painRegurgitation of foodRefusing to eat or being a very picky eater (especially in children)Poor weight gain or growth problems in childrenFeeling full very quicklyThroat tightness or discomfortCoughing or gagging during mealsNeeding to drink lots of water to wash food down

Inheritance

Multifactorial

Caused by a mix of several genes and environmental factors

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗NORD ↗

FDA & Trial Timeline

10 events
Apr 2026

DUPIXENT: New indication approved

FDAcompleted
Apr 2026DUPIXENT: New indication approved
FDAcompleted
Feb 2026DUPIXENT: New indication approved
FDAcompleted
Feb 2026Comparison of Eohilia With Dupixent on Esophagus Diameter in Patients With Eosinophilic Esophagitis.

Mayo Clinic — EARLY_PHASE1

TrialNOT YET RECRUITING
Dec 2025Trial of Partial Enteral Nutrition With Dairy Free Diet in Eosinophilic Esophagitis

Kate Farms Inc — NA

TrialNOT YET RECRUITING
Nov 2025A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis

Regeneron Pharmaceuticals — PHASE3

TrialRECRUITING
Aug 2025Surface EMG Testing on Swallowing in EoE Patients

Mayo Clinic

TrialRECRUITING
Aug 2025Trans-Cervical and Trans-abdominal Ultrasound for Monitoring Esophageal Thickness in Eosinophilic Esophagitis

Sheba Medical Center — NA

TrialNOT YET RECRUITING
Jul 2025Prevalence and Description of FIRE (Food Induced Immediate Response of the Esophagus) in the Pediatric Population With Eosinophilic Esophagitis

University Hospital, Angers

TrialRECRUITING
Jul 2025Local Clinical and Immunological Responses in Eosinophilic Esophagitis (EoE) Patients, Role of Mucosal Barrier Function and Type II Inflammation

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

2 available

Eohilia

budesonide· Takeda Pharmaceuticals U.S.A., Inc.Orphan Drug

treatment for 12 weeks in adult and pediatric patients 11 years of age and older with eosinophilic esophagitis (EoE)

Dupixent

dupilumab· Regeneron Pharmaceuticals, Inc.Orphan Drug

Treatment of adult and pediatric patients aged 12 years and older, weighing at least 40 kg, with eosinophilic esophagitis (EoE)

Clinical Trials

18 recruitingView all trials with filters →
Phase 31 trial
A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis
Phase 3
Actively Recruiting
PI: Clinical Trial Management (Regeneron Pharmaceuticals) · Sites: Phoenix, Arizona; Aurora, Colorado +4 more · Age: 06 yrs
Phase 42 trials
Effect of Dupilumab on the Muscle Function of the Esophagus (food Pipe) in Participants with Eosinophilic Esophagitis (EoE)
Phase 4
Actively Recruiting
· Sites: La Jolla, California · Age: 2299 yrs
A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)
Phase 4
Active
PI: Clinical Sciences & Operations (Sanofi) · Sites: Murrieta, California; San Francisco, California +28 more · Age: 1899 yrs
Phase 23 trials
Dupilumab Versus Topical Corticosteroid Effectiveness - Comparison in the Treatment of Stenotic EoE
Phase 2
Actively Recruiting
· Sites: Aurora, Colorado · Age: 1225 yrs
Zemaira Eosinophilic Esophagitis Pilot Study
Phase 2
Actively Recruiting
PI: Marc Rothenberg (Cincinnati Children's Hospital Medical Center) · Sites: Bethesda, Maryland; Cincinnati, Ohio · Age: 1870 yrs
A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis
Phase 2
Active
PI: Andrew W Lee, MD (Vice President, Clinical Research) · Sites: Dothan, Alabama; Glendale, Arizona +71 more · Age: 1875 yrs
N/A3 trials
EDN and Eosinophilic Esophagitis
N/A
Actively Recruiting
PI: Anaïs LEMOINE, Doctor (Assistance Publique - Hôpitaux de Paris) · Sites: Paris · Age: 217 yrs
Tolerability of Baked Dairy Protein in Eosinophilic Esophagitis Patients With Cow Milk Protein Trigger
N/A
Enrolling by Invitation
· Sites: Jerusalem · Age: 018 yrs
The Immune Directed Individualized Elimination Therapy (iDIET) Study
N/A
Active
PI: Evan S Dellon, MD, MPH (University of North Carolina, Chapel Hill) · Sites: Chapel Hill, North Carolina · Age: 1680 yrs
Other9 trials
Natural History and Genetics of Food Allergy and Related Conditions
Actively Recruiting
PI: Pamela A Guerrerio, M.D. (National Institute of Allergy and Infectious Disea) · Sites: Bethesda, Maryland · Age: 099 yrs
Characteristics and Inflammatory Markers in Children with Eosinophilic Esophagitis (EoE)
Actively Recruiting
· Sites: San Diego, California · Age: 165 yrs
Prospective Registry of EoSinophilic esOphagitis
Actively Recruiting
· Sites: Milan, Lombardy
Prevalence and Description of FIRE (Food Induced Immediate Response of the Esophagus) in the Pediatric Population With Eosinophilic Esophagitis
Actively Recruiting
PI: Anne HOPPE (University Hospital of Angers) · Sites: Angers; Lille · Age: 617 yrs
Local Clinical and Immunological Responses in Eosinophilic Esophagitis (EoE) Patients, Role of Mucosal Barrier Function and Type II Inflammation
Actively Recruiting
· Sites: Amsterdam, North Holland · Age: 1875 yrs
Esophageal String Test Monitoring to Monitor Eosinophilic Esophagitis During Oral Immunotherapy
Actively Recruiting
PI: Jonathan M Spergel, MD, PhD (Children's Hospital of Philadelphia) · Sites: Philadelphia, Pennsylvania · Age: 717 yrs
Molecular Basis of Food Allergy
Enrolling by Invitation
PI: Jonathan M Spergel, MD, PhD (Children's Hospital of Philadelphia) · Sites: Philadelphia, Pennsylvania · Age: 065 yrs
Surface EMG Testing on Swallowing in EoE Patients
Actively Recruiting
PI: Karthik Ravi, MD (Mayo Clinic) · Sites: Rochester, Minnesota · Age: 1899 yrs
A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care
Actively Recruiting
PI: Clinical Trial Management (Regeneron Pharmaceuticals) · Sites: Phoenix, Arizona; Sun City, Arizona +52 more · Age: 199 yrs

No specialists are currently listed for NON RARE IN EUROPE: Eosinophilic esophagitis.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Financial Resources

2 resources
Eohilia(budesonide)Takeda Pharmaceuticals U.S.A., Inc.
Dupixent(dupilumab)Regeneron Pharmaceuticals, Inc.

Travel Grants

No travel grants are currently matched to NON RARE IN EUROPE: Eosinophilic esophagitis.

Search all travel grants →NORD Financial Assistance ↗

Community

Open NON RARE IN EUROPE: Eosinophilic esophagitisForum →

No community posts yet. Be the first to share your experience with NON RARE IN EUROPE: Eosinophilic esophagitis.

Start the conversation →

Latest news about NON RARE IN EUROPE: Eosinophilic esophagitis

No recent news articles for NON RARE IN EUROPE: Eosinophilic esophagitis.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.What is the best treatment approach for my specific case — diet, medication, or both?,How often will I need endoscopies to monitor my condition?,Should I see an allergist to identify my food or environmental triggers?,Am I a candidate for dupilumab (Dupixent), and what are the pros and cons?,What are the signs that my esophagus is narrowing, and when would I need a dilation procedure?,How do I safely follow an elimination diet without missing important nutrients?,What should I do if food gets completely stuck and I cannot swallow?

Common questions about NON RARE IN EUROPE: Eosinophilic esophagitis

What is NON RARE IN EUROPE: Eosinophilic esophagitis?

Eosinophilic esophagitis, often called EoE for short, is a chronic condition where a type of white blood cell called an eosinophil builds up in the esophagus — the tube that carries food from your mouth to your stomach. Normally, eosinophils are not found in the esophagus, but in EoE they gather there and cause inflammation, which makes swallowing difficult and painful over time. EoE is considered an allergic or immune-driven disease, and it is closely linked to food allergies and environmental allergies like pollen. The most common symptoms include trouble swallowing solid foods, food gettin

How is NON RARE IN EUROPE: Eosinophilic esophagitis inherited?

NON RARE IN EUROPE: Eosinophilic esophagitis follows a multifactorial inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

Are there clinical trials for NON RARE IN EUROPE: Eosinophilic esophagitis?

Yes — 18 recruiting clinical trials are currently listed for NON RARE IN EUROPE: Eosinophilic esophagitis on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

What treatment and support options exist for NON RARE IN EUROPE: Eosinophilic esophagitis?

2 patient support programs are currently tracked on UniteRare for NON RARE IN EUROPE: Eosinophilic esophagitis. See the treatments and support programs sections for copay assistance, eligibility, and contact details.